Video: Knock on Wood| Webinar: ACR/CHEST ILD Guidelines in Practice
fa-facebookfa-linkedinfa-youtube-playfa-rss

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Vasculitis Guidelines in Focus, Part 4: Polyarteritis Nodosa

Michael Putman, MD  |  Issue: December 2021  |  September 22, 2021

From the guideline—Recommendation: For patients with clinical manifestations of deficiency of adenosine deaminase 2 (DADA2), we strongly recommend treatment with tumor necrosis factor [TNF] inhibitors over glucocorticoids alone.

Q: What led to the strong recommendation in the new guideline for TNF inhibitors in DADA2? And to follow up on that, who do you think we should be screening, and how do you recommend screening to find those people you’re going to treat with TNF inhibitors?

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Dr. Springer: TNF inhibitors have become an important treatment for patients with DADA2 who have vasculitis features. Based on data from the NIH [National Institutes of Health], TNF inhibitors are especially effective at preventing recurrent strokes.9 TNF inhibitors aren’t the first treatment we reach for in primary PAN, but they can make a huge difference in patients with DADA2.

Who to screen is a more difficult question. There isn’t a consensus I know of. I think there are some clues in patients—anybody with a family history of PAN or PAN-like features, anybody who has had childhood onset or who has had neurologic involvement, like strokes—they’re the ones I would strongly consider for a diagnosis of DADA2.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

I do think that childhood-onset PAN patients should be screened for DADA2. But it doesn’t make sense to screen every adult patient with PAN for DADA2. A study that looked at an adult primary PAN population through the Vasculitis Clinical Research Consortium (VCRC) cohort found a prevalence of only about 5% of patients who had ADA2 gene mutations and met criteria for DADA2.10

There are a couple of different ways to confirm the diagnosis and screen. One would be to check the genetic testing; testing for the ADA2 gene (formerly the CECR1 gene) is commercially available in immunodeficiency or periodic fever panels.

The other way is to check peripheral ADA2 levels; you can check the absolute levels or the enzyme activity. The only place I know of that is CLIA-certified to do this is Duke University School of Medicine, Durham, N.C. (Note: For information about ADA2 activity testing, contact [email protected].)

I think there’s going to be point-of-care testing, but that’s not available yet. To really confirm the diagnosis, I would probably get both the ADA2 gene testing and peripheral ADA2 levels. It is important to keep adults in mind, though. A lot of people think of DADA2 as just a childhood disease, but I have diagnosed several adults with DADA2.

Page: 1 2 3 4 5 6 | Single Page
Share: 

Filed under:Clinical Criteria/GuidelinesConditionsVasculitis Tagged with:Guidelinespolyarteritis nodosaVasculitisVasculitis Foundation

Related Articles

    DADA2: A New Disease for Rheumatologists to Understand

    January 17, 2019

    BETHESDA, MD—Rheumatologists from the National Institutes of Health (NIH) and from Jerusalem, Israel, have identified deficiency of adenosine deaminase 2 (DADA2) as an important cause of familial polyarteritis nodosa, which tends to present in childhood and can manifest with hematologic, immunologic and inflammatory signs, says Chip Chambers, MD, founder and president of the DADA2 Foundation….

    New Study Sheds Light on Deficiency of Adenosine Deaminase 2 (DADA2)

    April 15, 2020

    Since it was first described, the spectrum of disease caused by deficiency of adenosine deaminase 2 (DADA2) has been broadening. Features described include systemic vascular and inflammatory features and recurrent stroke, which overlap with childhood-onset poly­arteritis nodosa (PAN). Previous data show that DADA2 has extensive genotypic and phenotypic variation.1 Results from a recently published study…

    DADA2 Research Reveals Mechanisms & Possible Gene Therapy

    February 18, 2018

    SAN DIEGO—An increasing number of patients is being identified with deficiency of adenosine deaminase type 2 (DADA2); fortunately, researchers and clinicians continue to better understand the genetic disease as well, experts said in a session at the 2017 ACR/ARHP Annual Meeting Nov. 3–8. The childhood-onset disease involves loss-of-function mutations to the CECR1 gene (i.e., cat…

    Case Report: Diagnosing, Treating Hepatitis B-Linked Polyarteritis Nodosa

    September 17, 2019

    Hepatitis B virus (HBV) associated polyarteritis nodosa (PAN) is an increasingly rare vasculitis in developed countries due to advances in HBV vaccination and antiviral therapy. However, the condition does persist, and rheumatologists should consider it when evaluating vasculitis cases. Below, we discuss a case that illustrates the varied clinical presentations PAN can encompass. A high…

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
fa-facebookfa-linkedinfa-youtube-playfa-rss
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences